Psychology of Drug Use and Abuse — CNS Depressants & Anxiety Medications

Case Study: Nikki F.—A Personal Narrative on Prescription Drug Misuse

  • Background
    • Desired to avoid alcohol because of father’s alcoholism → perceived prescription drugs as a “safer” alternative.
    • Self-medicated “pretty bad anxiety” with friends’ pills (principally benzodiazepines: Xanax / Valium).
  • Escalation Pattern
    • Initial relief from one tablet → tolerance → doubled dose → multiple doses throughout the day.
    • Entered a state of constant, low-grade intoxication (“buzzed relaxation”).
  • Functional Consequences
    • Fell asleep on subway → purse stolen.
    • Cognitive/occupational impairment → fired from job.
    • Social damage → alienated sister after confrontation.
  • “Rock Bottom”
    • Financial collapse → moved back with parents; threat of homelessness finally motivated treatment.
  • Treatment & Recovery
    • Entered rehab; experienced difficult withdrawal (“comedown”).
    • Post-detox insight: lost job, friends, money, autonomy.
    • Maintains daily vigilance against denial; frames sobriety as an ongoing fight.

Understanding Anxiety

Core Definition

  • A future-oriented mood state characterized by worry, vigilance, and physiological arousal, distinct from immediate “fear.”

Symptom Clusters (“The Anxiety Experience”)

  • Motor Tension
    • Shakiness, muscular tension, restlessness.
  • Autonomic Hyperactivity
    • Sweating, pounding heart, stomach tightness, facial flushing.
  • Apprehensive Expectation
    • Persistent thoughts of anxiety, fear, rumination.
  • Vigilance
    • Impatience, hyper-attentiveness, insomnia.

Three-Component Model (Figure 18.1)

  • Potential Stressors
    • Failures, personal losses, frightening events, time pressure, insults.
  • Cognitive Appraisal → “Stressor perceived as a threat.”
  • Bodily Effects
    • \text{Shallow breathing}, \text{pounding heart}, tense muscles, digestive problems, sleep disturbance, fatigue, psychosomatic illness.
  • Upsetting Thoughts
    • Anger, fears, self-doubts, repeated “danger” cognitions, health worries.
  • Ineffective Behavior
    • Escape, avoidance, inflexibility, poor judgment, indecision, inefficiency, aggression, drug use.

Adaptive vs. Maladaptive Anxiety

  • Small amounts are adaptive—motivate preparation, caution, performance.
  • Ethical dilemma: Should we medicate “normal” anxiety?
    • Over-medicalization vs. legitimate distress relief.

Pharmacological Management of Anxiety & Sleep

Dose-Dependent CNS-Depressant Continuum

  • Anxiolytic → Sedative → Hypnotic → Anesthetic → Coma / Death.
  • Most modern agents carry a high therapeutic index; overdose rare unless combined with other depressants (e.g., alcohol, opioids).

Historical Evolution of Anxiolytics

Barbiturates (Pre-1950s)

  • Prototype: Phenobarbital.
  • Powerful CNS depressants; narrow therapeutic window; high overdose/lethal risk.

Propanediol Carbamates (“Non-barbiturate Sedatives”)

  • Agents: Meprobamate (Miltown, Equanil), Methaqualone (Quaalude / Sopor).
  • Mechanism: muscle relaxation via decreased acetylcholine (ACH) action.
  • Side-effects: drowsiness, intoxication, impaired motor coordination, REM-suppression, physical dependence → tolerance & withdrawal.
  • 1950s marketing (“Age of Anxiety”)
    • Huge advertising campaigns; portrayed as universally safe and versatile.
    • Lack of formal diagnostic guidelines fueled mass prescriptions.

Benzodiazepines (1960 onward)

  • First-in-class: Chlordiazepoxide (Librium) → quickly followed by Diazepam (Valium), Lorazepam (Ativan), Alprazolam (Xanax), etc.
  • Advantages vs. barbiturates
    • Target anxiety at lower sedation level.
    • Wide safety margin; minimal respiratory depression.
    • Low acute toxicity; slower tolerance build-up; milder withdrawal.
  • Clinical uses
    • Acute anxiety, panic attacks, phobias.
    • Alcohol-withdrawal management.
    • Short-term insomnia (REM suppression but minimal “hangover”).
    • Not recommended for chronic generalized anxiety due to dependence risk.

Non-benzodiazepine Anxiolytics

  • Buspirone (acts on serotonin).
  • Often chosen for long-term generalized anxiety when sedation/abuse liability must be minimized.

Pharmacodynamics—GABA(_A) Receptor Complex

  • Pentameric chloride ion channel (subunits: \alpha\,\beta\,\gamma).
  • Multiple allosteric binding sites:
    • BZD Site: increases frequency of Cl⁻ channel opening in presence of \text{GABA}.
    • Barbiturate Site: increases duration of opening.
    • Propofol / Ethanol / Volatile anesthetics: distinct modulatory pockets.
  • Net effect: membrane hyper-polarization → CNS inhibition → anxiolysis, sedation, anticonvulsant action, muscle relaxation.

Benzodiazepines in Detail

Key Therapeutic Characteristics

  • Produce anxiolysis at doses with fewer side-effects than earlier sedatives.
  • Drowsiness less pronounced; high lethal dose unless combined with other depressants.
  • Useful for alcohol detox (cross-tolerant at GABA(_A) receptor).
  • Anterograde amnesia—useful for medical procedures; problematic for daily function.

Representative Agents by Elimination Half-Life (Table 13.2 Condensed)

  • Long-Acting (>24 h)
    • Diazepam (Valium) ≈ 24 h; active metabolite nordiazepam.
    • Chlordiazepoxide (Librium) ≈ 60–100 h.
    • Flurazepam (Dalmane) ≈ 10–24 h, but active metabolite lasts 80 h +.
  • Intermediate (≈15–35 h)
    • Lorazepam (Ativan) ≈ 15 h, no active metabolite.
    • Clonazepam (Klonopin) ≈ 30 h.
    • Estazolam (ProSom) ≈ 18 h.
  • Short-Acting (

Clinical Selection Principles

  • Sleep-onset insomnia: short-acting (e.g., triazolam) to avoid daytime sedation.
  • Generalized anxiety: intermediate agents to cover day without accumulation.
  • Older adults / hepatic disease: choose drugs without active metabolites (lorazepam, oxazepam, temazepam).

Dependence, Tolerance & Withdrawal

  • Physical dependence
    • GABA(_A) receptor down-regulation → need higher dose for same effect (tolerance).
  • Psychological dependence
    • Patients may overvalue immediate relief; fear of baseline anxiety → compulsive use.
  • Cross-tolerance with other CNS depressants (alcohol, barbiturates).
  • Withdrawal / Abstinence Syndrome
    • Rebound insomnia & anxiety, tremor, sweating, irritability.
    • High-dose, long-term users risk seizures.
  • Tapering as a “psychological journey”
    • Gradual dose reduction; CBT support; patient education on transient rebound phenomena.

Ethical, Philosophical & Practical Implications

  • Medicalization vs. Resilience
    • Where is the threshold between adaptive anxiety and pathology?
    • Risk of prescribing for transient, situational stress vs. providing needed relief.
  • Informed Consent & Social Context
    • Patients must understand tolerance, dependence, safe duration (~2–4 weeks for many guidelines).
    • Social-media narratives (e.g., “benzobuddies”) influence patient perceptions—clinicians should address misinformation and fears openly.
  • Prescriber Responsibility
    • Use lowest effective dose, shortest duration.
    • Screen for substance-use disorders; coordinate with psychotherapy.
    • Consider non-pharmacological interventions (CBT, mindfulness, lifestyle modifications) as first-line for mild-to-moderate anxiety.

Key Take-Home Points

  • Anxiety is multifaceted; small amounts are adaptive but can become debilitating.
  • CNS depressant drugs fall on a dose-dependent continuum from anxiolysis to fatal respiratory depression.
  • Propanediol carbamates marked the 1950s “Age of Anxiety” but carried significant dependence risk.
  • Benzodiazepines revolutionized anxiolysis with improved safety but are not free of abuse liability.
  • Clinical use demands balance: efficacy vs. dependence, short-term relief vs. long-term coping skills.
  • Patient stories like Nikki F.’s highlight the slippery slope from self-medication → tolerance → life disruption → rehabilitation.